Intracranial Solitary Fibrous Tumour Management: A French Multicentre Retrospective Study.
hemangiopericytoma
intracranial
recurrence
solitary fibrous tumour
surgery
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Jan 2023
24 Jan 2023
Historique:
received:
01
12
2022
revised:
09
01
2023
accepted:
20
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
12
2
2023
Statut:
epublish
Résumé
Intracranial solitary fibrous tumour (iSFT) is an exceptional mesenchymal tumour with high recurrence rates. We aimed to analyse the clinical outcomes of newly diagnosed and recurrent iSFTs. We carried out a French retrospective multicentre ( Eighty-eight patients were included with a median age of 54.5 years. New iSFT cases were treated with gross tumour resection (GTR) ( GTR provided benefits as a first treatment for iSFTs. However, approximately 40% of patients experienced relapse, which remains a challenging state.
Sections du résumé
BACKGROUND
BACKGROUND
Intracranial solitary fibrous tumour (iSFT) is an exceptional mesenchymal tumour with high recurrence rates. We aimed to analyse the clinical outcomes of newly diagnosed and recurrent iSFTs.
METHODS
METHODS
We carried out a French retrospective multicentre (
RESULTS
RESULTS
Eighty-eight patients were included with a median age of 54.5 years. New iSFT cases were treated with gross tumour resection (GTR) (
CONCLUSION
CONCLUSIONS
GTR provided benefits as a first treatment for iSFTs. However, approximately 40% of patients experienced relapse, which remains a challenging state.
Identifiants
pubmed: 36765662
pii: cancers15030704
doi: 10.3390/cancers15030704
pmc: PMC9913492
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Neurooncol. 2017 Feb;131(3):525-546
pubmed: 27853959
BMC Cancer. 2021 Aug 12;21(1):915
pubmed: 34384377
J Clin Neurosci. 2015 Apr;22(4):718-25
pubmed: 25744076
Neurosurg Rev. 2006 Apr;29(2):145-53
pubmed: 16391940
J Neurosurg. 2010 Aug;113(2):333-9
pubmed: 20367074
World Neurosurg. 2017 Nov;107:495-505
pubmed: 28823664
Cancer. 2005 Dec 1;104(11):2457-65
pubmed: 16222690
J Neurooncol. 1992 Nov;14(3):277-87
pubmed: 1460491
Cancer. 2004 Apr 1;100(7):1491-7
pubmed: 15042684
J Oncol Pharm Pract. 2019 Sep;25(6):1301-1304
pubmed: 29945534
Neurosurgery. 2001 Apr;48(4):756-62; discussion 762-3
pubmed: 11322435
Cancer. 2011 Nov 1;117(21):4939-47
pubmed: 21480200
Brain Pathol. 2019 Jan;29(1):18-27
pubmed: 29600523
Bull Cancer. 2020 Dec;107(12):1260-1273
pubmed: 33160607
J Neurosurg. 2018 Dec 1;129(6):1384-1396
pubmed: 29372881
Acta Neurochir (Wien). 2012 Sep;154(9):1647-51
pubmed: 22790838
Acta Neurochir (Wien). 2021 Jul;163(7):1895-1905
pubmed: 33742279
Neurosurgery. 2008 Oct;63(4):720-6; author reply 726-7
pubmed: 18981882
J Surg Oncol. 1983 Mar;22(3):167-70
pubmed: 6682161
J Neurosurg. 2017 Mar;126(3):744-754
pubmed: 27104850
Neurosurgery. 1989 Oct;25(4):514-22
pubmed: 2797389
J Natl Cancer Inst. 1996 Jun 5;88(11):764-5
pubmed: 8637034
Surg Neurol. 1985 Mar;23(3):227-36
pubmed: 3975803
Lancet Oncol. 2020 Mar;21(3):456-466
pubmed: 32066540
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
J Neurosurg. 2011 Mar;114(3):747-55
pubmed: 20672899
Surg Neurol. 2003 Jan;59(1):47-53; discussion 53-4
pubmed: 12633961
Can J Neurol Sci. 2020 Jan;47(1):18-29
pubmed: 31607282
World Neurosurg. 2014 Mar-Apr;81(3-4):556-62
pubmed: 24239740
Cancer Res Treat. 2022 Jan;54(1):65-74
pubmed: 33781051
J Clin Neurosci. 2011 Nov;18(11):1500-4
pubmed: 21917462
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):784-90
pubmed: 22867893
Med Pediatr Oncol. 2003 Mar;40(3):192-4
pubmed: 12518351